RT Journal Article SR Electronic T1 Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer JF Journal for ImmunoTherapy of Cancer JO J Immunother Cancer FD BMJ Publishing Group Ltd SP e002552 DO 10.1136/jitc-2021-002552 VO 9 IS 7 A1 Matthew D Galsky A1 Arjun V Balar A1 Peter C Black A1 Matthew T Campbell A1 Gail S Dykstra A1 Petros Grivas A1 Shilpa Gupta A1 Christoper J Hoimes A1 Lidia P Lopez A1 Joshua J Meeks A1 Elizabeth R Plimack A1 Jonathan E Rosenberg A1 Neal Shore A1 Gary D Steinberg A1 Ashish M Kamat YR 2021 UL http://jitc.bmj.com/content/9/7/e002552.abstract AB A number of immunotherapies have been developed and adopted for the treatment of urothelial cancer (encompassing cancers arising from the bladder, urethra, or renal pelvis). For these immunotherapies to positively impact patient outcomes, optimal selection of agents and treatment scheduling, especially in conjunction with existing treatment paradigms, is paramount. Immunotherapies also warrant specific and unique considerations regarding patient management, emphasizing both the prompt identification and treatment of potential toxicities. In order to address these issues, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in the field of immunotherapy for urothelial cancer. The expert panel developed this clinical practice guideline (CPG) to inform healthcare professionals on important aspects of immunotherapeutic treatment for urothelial cancer, including diagnostic testing, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QOL) considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with urothelial cancer.